Brett King, MD
Dermatology · Fairfield, CTNPI 1336324060
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Pfizer at 32.2% of the total. Among dermatology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,335 payments — averaging $1890.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$814K
- Lilly USA, LLC$348K
- AbbVie$274K
- Eli Lilly$260K
- Sanofi$241K
- Regeneron Healthcare Solutions, Inc.$233K
- plus $353K from 22 others
Across 262 payments — averaging $14,253 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.6M
- Eli Lilly$1.2M
- Sun Pharmaceutical Industries Inc.$886K
- E.r. Squibb & Sons, L.L.C.$66K
- AbbVie$18K
What the payments were for
- Consulting fees$1,056,85042%
- Speaking & faculty fees$1,180,30447%
- Grants$2,2330%
- Travel & lodging$264,18910%
- Food & beverage$19,7601%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 344 | $813,683 |
| Lilly USA, LLC | 123 | $348,155 |
| AbbVie | 185 | $274,029 |
| Eli Lilly | 149 | $259,844 |
| Sanofi | 136 | $241,140 |
| Regeneron Healthcare Solutions, Inc. | 177 | $233,471 |
| Incyte Corporation | 94 | $112,918 |
| Sun Pharmaceutical Industries Inc. | 37 | $78,328 |
| E.r. Squibb & Sons, L.L.C. | 18 | $46,758 |
| Janssen Global Services, LLC | 12 | $27,750 |
| Sanofi US Services Inc. | 1 | $26,167 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $10,005 |
| LEO Pharma Inc. | 8 | $9,474 |
| Merck | 6 | $8,011 |
| Almirall LLC | 5 | $7,580 |
| Amgen | 4 | $5,459 |
| Aclaris Therapeutics, Inc. | 1 | $5,049 |
| Galderma Laboratories, L.p. | 3 | $5,025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $4,414 |
| GSK | 1 | $2,500 |
| Johnson & Johnson | 3 | $1,870 |
| Janssen Research & Development, LLC | 2 | $877 |
| Sanofi-aventis U.S. LLC | 14 | $551 |
| Dermavant Sciences, Inc. | 2 | $203 |
| UCB, Inc. | 2 | $103 |
| Arcutis Biotherapeutics, Inc. | 1 | $26 |
| Strata Skin Sciences, Inc. | 1 | $14 |
| Mayne Pharma Commercial LLC | 2 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,523,412 in reported general payments places this provider in the 95th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 41 | $140,402 |
| RinvoqUpadacitinib | 11 | $69,880 |
| OlumiantBaricitinib | 11 | $59,470 |
| SiliqBrodalumab | 11 | $50,783 |
| Minoxidil | 228 | $5,154 |
| Dutasteride | 62 | $3,691 |
| Hydroxychloroquine Sulfate | 64 | $2,464 |
| Spironolactone | 116 | $1,664 |
| Doxycycline Hyclate | 22 | $1,171 |
| Clobetasol Propionate | 24 | $780 |
| Doxycycline Monohydrate | 18 | $633 |
| Finasteride | 34 | $544 |
| ValacyclovirValacyclovir Hcl | 11 | $284 |
| Triamcinolone Acetonide | 29 | $283 |
| MethotrexateMethotrexate Sodium | 12 | $183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $274,029 | $69,88011 claims |
| Lilly USA, LLCOlumiant | $348,155 | $59,47011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 dermatology providers in Connecticut.
Other dermatology in Fairfield
- Brittany CraiglowFairfield$1.9M
- Michael PayetteCromwell$3.2M
- Bruce StroberCromwell$2.9M
- Mona ShahriariCromwell$2.2M
- Jeremy MossMadison$2M
- Meagen McCuskerEnfield$1.8M
- Marcus McFerrenOrange$872K
- Christopher BunickNew Haven$661K
- Keith ChoateNew Haven$362K
- Kim NicholsGreenwich$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.